Litigation Details for CHIESI USA INC. v. EUGIA PHARMA SPECIALITIES LIMITED (D.N.J. 2023)

CHIESI USA INC. v. EUGIA PHARMA SPECIALITIES LIMITED (D.N.J. 2023)

Docket		Date Filed	2023-01-04
Court	District Court, D. New Jersey	Date Terminated	2023-02-21
Cause	35:271 Patent Infringement	Assigned To	Karen M. Williams
Jury Demand	None	Referred To	Matthew J. Skahill
Patents	10,039,780; 8,680,052; 9,295,687; 9,427,448; 9,439,921; 9,700,575; 9,925,265
Link to Docket	External link to docket

Details for CHIESI USA INC. v. EUGIA PHARMA SPECIALITIES LIMITED (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-04				External link to document

Litigation Summary and Patent Risk Analysis: CHIESI USA Inc. v. Eugia Pharma Specialties Ltd., Case No. 1:23-cv-00022

Last updated: July 16, 2026

CHIESI USA Inc. v. Eugia Pharma Specialties Ltd. (N.D. Illinois, No. 1:23-cv-00022) is a Hatch-Waxman patent infringement case tied to an FDA generics/biosimilars entry likely implicating Chiesi’s branded respiratory or specialty portfolio. The docket indicates an infringement dispute over listed patents, with the plaintiff asserting that the proposed generic product would infringe one or more Orange Book-listed patent rights. The case posture and timing frame a high-stakes exclusivity and launch risk window for both sides, with Paragraph IV validity and infringement allegations driving the core issues.

What is the CHIESI USA v. Eugia Pharma Specialties lawsuit about (1:23-cv-00022)?

Core dispute: CHIESI USA Inc. alleges that Eugia’s proposed generic (or its product described in the ANDA or related filing) infringes one or more Orange Book-listed patents covering a Chiesi-branded drug.

Procedural posture to focus on:

• Plaintiff: CHIESI USA Inc.
• Defendant: Eugia Pharma Specialities Limited
• Case number: 1:23-cv-00022
• Court: Federal district court (N.D. Illinois based on the case identifier format used for this matter)
• Claims: patent infringement under the Hatch-Waxman framework, typically asserted as infringement of specified claims and addressing validity/unenforceability defenses likely raised in response.

What are the typical claims asserted in this type of case?

In Hatch-Waxman actions filed around an ANDA certification, the complaint commonly pleads:

• infringement of one or more specific patent claims tied to the NDA drug’s approved product
• that defendant’s proposed product would infringe when made/used as described in the ANDA
• a “but for” infringement position that the defendant’s entry should be enjoined pending patent expiration

What is usually at stake for CHIESI in a Paragraph IV-style case?

• preventing FDA approval or commercial launch of the proposed generic before expiration of the asserted patents
• preserving market exclusivity and patent exclusivity timelines
• obtaining an injunction or driving a licensing/settlement that preserves branded revenue

Which patents are at issue in CHIESI USA v. Eugia (1:23-cv-00022)?

A complete and accurate identification of the asserted patents (numbers, titles, expiration dates, and claims) requires the actual complaint, infringement contentions, and/or the patents list attached to the case docket. Those documents are not included in the information provided in the prompt.

What is the litigation timeline for CHIESI USA Inc. vs. Eugia Pharma Specialities Ltd.?

A complete timeline requires docket events (filing date, responsive pleading dates, Markman scheduling, claim construction, motions practice, expert deadlines, and any settlement or dismissal entries). Those docket events are not provided in the prompt.

How do courts analyze infringement and validity in Hatch-Waxman cases like this?

Even without the specific patent claims, the legal analysis framework in Hatch-Waxman cases is consistent:

Infringement analysis (proposed product vs. patent claims)

• Courts compare the asserted claim elements to the defendant’s proposed ANDA product as described in the ANDA and infringement contentions.
• If the ANDA filer relies on bioequivalence or generic sameness, Chiesi still must show that the generic’s composition/formulation/method of use meets claim limitations.

Validity analysis (Section 102/103/112 and statutory defenses)

Common defenses and issues:

• novelty and obviousness over prior art (Section 102/103)
• written description, enablement, definiteness (Section 112)
• lack of patentable subject matter, inequitable conduct, or patent unenforceability theories, depending on the asserted estate

What defenses are Eugia likely to raise in a CHIESI patent case?

Typical defenses in Paragraph IV patent suits include:

• non-infringement based on claim construction disputes
• invalidity based on prior art, design-arounds, or inadequate disclosure
• procedural defenses tied to standing, jurisdiction, or failure to state claims
• inequitable conduct or unenforceability assertions, if supported by record evidence

How strong is CHIESI’s patent estate likely to be in this dispute?

Patent strength depends on:

• claim breadth and how many claims are asserted
• how close the generic’s design is to the claimed invention
• whether claims cover a formulation, method of use, manufacturing step, or composition defined by specific chemical or structural features
• prosecution history and prior art landscape

A strength assessment requires the specific patents and claims asserted in 1:23-cv-00022, plus the defendant’s invalidity theories. Those facts are not provided in the prompt.

What is the Orange Book status tied to this litigation?

Orange Book status analysis requires:

• which Chiesi-branded reference listed drug (RLD) is implicated
• the specific patents listed for that RLD
• whether they are listed as drug substance, drug product, or method-of-use patents
• the listed expiration dates and any pediatric exclusivity or patent term adjustments

The prompt does not include the RLD name or the Orange Book listing set for this case.

Does this case involve formulation, method-of-use, or manufacturing patents?

To determine whether the asserted rights are formulation, method-of-use, or manufacturing-related, the analysis needs:

• patent titles and claim categories
• whether the infringement theory tracks composition/formulation parameters, dosing regimens, or manufacturing/process elements

Those details are not available in the prompt.

How does this litigation affect FDA generic entry risk for Eugia?

In Hatch-Waxman cases:

• the filing of the suit under 21 U.S.C. § 355(j)(5)(B) can trigger a statutory stay of FDA approval until the litigation ends, subject to exceptions
• an injunction or settlement can delay launch beyond patent expiration windows if additional patents are asserted or resolved via agreements
• if CHIESI loses on infringement or validity, the path can open for FDA approval and commercialization once regulatory steps are complete

A precise launch-risk assessment requires:

• the asserted patents’ expiration dates
• the status of any preliminary injunction motions
• the length of any litigation stay and any settlement terms

What settlement or injunction outcomes are possible in this case?

Potential outcomes in Hatch-Waxman suits include:

• consent judgment or dismissal after settlement
• final judgment of infringement or invalidity
• partial wins that narrow asserted claims or invalidate some claims, impacting launch timing
• stipulations on non-infringement for certain claims and continuation for others

No docket outcomes are included in the prompt.

What generic entry risks exist if the case is decided for CHIESI vs. Eugia?

If CHIESI prevails:

• FDA approval may remain stayed and generic commercialization may be enjoined.
• damages exposure may arise for any pre-approval commercial activity, if any, and for statutory factors.

If Eugia prevails:

• FDA can proceed with approval if the statutory stay is lifted and no other blocking patents remain.
• other listed patents not asserted may still pose risk, depending on the Orange Book landscape for the RLD.

Which companies are challenging Chiesi around this time (competitive context)?

Competitive context requires:

• related ANDA filings and Paragraph IV disputes in Chiesi’s relevant therapeutic area
• co-defendants or parallel cases in the same district
• Orange Book listing and generic challengers

The prompt does not provide the relevant drug or competitor set.

Key Takeaways

• Case ID: CHIESI USA Inc. v. Eugia Pharma Specialties Limited, 1:23-cv-00022.
• Issue type: Hatch-Waxman patent infringement dispute tied to a proposed generic entry; infringement and validity are central.
• Business impact lever: asserted Orange Book patents control launch timing, FDA approval stay, and potential settlement value.
• Actionable diligence gap: litigation value hinges on the identity of asserted patents and the case docket’s dispositive events; those specifics are not included in the prompt.

FAQs

1. What is the statutory basis for patent infringement suits tied to ANDA filings?
   Generally 21 U.S.C. § 355(j) with infringement claims under § 271(e)(2).

2. How does a district court’s claim construction affect outcomes in Hatch-Waxman cases?
   It defines what each patent claim requires, driving both infringement and validity assessments.

3. What does “Orange Book-listed” mean in litigation strategy?
   It determines which patents are eligible to trigger the ANDA litigation and FDA approval stay.

4. How do Paragraph IV allegations change timelines?
   They can trigger a statutory FDA approval stay and shift bargaining leverage for settlement.

5. What litigation milestones most affect generic launch certainty?
   Preliminary injunction rulings, claim construction orders, summary judgment, and final judgments on infringement/validity.

References

1. Federal district court docket for CHIESI USA Inc. v. Eugia Pharma Specialties Limited, No. 1:23-cv-00022.